Using the NYHA Classification as Forecasting Tool for Hospital Readmission and Mortality in Heart Failure Patients with COVID-19.
Ioana Mihaela CituCosmin CîtuFlorin GorunRadu NeamtuAndrei MotocBogdan BurleaOvidiu RoscaFelix BratosinSamer HosinDiana ManolescuRaul PatrascuOana-Maria GorunPublished in: Journal of clinical medicine (2022)
During the COVID-19 pandemic, it was observed that patients with heart disease are more likely to be hospitalized and develop severe COVID-19. Cardiac disease takes the top position among patient comorbidities, heart failure (HF) prevalence reaching almost 5% in the general population older than 35 years in Romania. This retrospective study aimed to determine the potential use of the NYHA classification for HF in hospitalized patients with COVID-19 as prognostic tool for in-hospital mortality, length of hospitalization, and probability of rehospitalization for HF decompensation. We observed that patients with advanced HF had a history of significantly more comorbid conditions that are associated with worse disease outcomes than the rest of patients classified as NYHA I and II. However, regardless of existing diseases, NYHA III, and, especially, NYHA IV, patients were at greatest risk for mortality following SARS-CoV-2 infection. They required significantly longer durations of hospitalization, ICU admission for mechanical ventilation, and developed multiple severe complications. NYHA IV patients required a median duration of 20 days of hospitalization, and their in-hospital mortality was as high as 47.8%. Cardiac biomarkers were significantly altered in patients with SARS-CoV-2 and advanced HF. Although the study sample was small, all patients with NYHA IV who recovered from COVID-19 required a rehospitalization in the following month, and 65.2% of the patients at initial presentation died during the next six months. The most significant risk factor for mortality was the development of severe in-hospital complications (OR = 4.38), while ICU admission was the strongest predictor for rehospitalization (OR = 5.19). Our result highlights that HF patients continue to be vulnerable post SARS-CoV-2 infection. Physicians and policymakers should consider this population's high likelihood of hospital readmissions when making discharge, hospital capacity planning, and post-discharge patient monitoring choices.
Keyphrases
- sars cov
- heart failure
- end stage renal disease
- ejection fraction
- mechanical ventilation
- newly diagnosed
- chronic kidney disease
- risk factors
- intensive care unit
- emergency department
- coronavirus disease
- primary care
- left ventricular
- prognostic factors
- physical activity
- deep learning
- metabolic syndrome
- climate change
- cardiovascular disease
- coronary artery disease
- respiratory syndrome coronavirus
- cardiac resynchronization therapy
- drug induced
- weight loss
- respiratory failure